SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.

abstract：AIM:No definite factors predict blood pressure response to angiotensin-converting enzyme-inhibitors. The aim of this study was to test the association of gene polymorphisms of the renin-angiotensin-aldosterone system with essential hypertension and anthropometric variables, intermediate phenotypes and gene polymorphism...

journal_title：Pharmacogenomics

authors： Filigheddu F,Argiolas G,Bulla E,Troffa C,Bulla P,Fadda S,Zaninello R,Degortes S,Frau F,Pitzoi S,Glorioso N

更新日期：2008-10-01 00:00:00

abstract：:Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

journal_title：Pharmacogenomics

authors： Ferrell PB Jr,McLeod HL

更新日期：2008-10-01 00:00:00

abstract：:Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

journal_title：Pharmacogenomics

authors： Jain KK

更新日期：2001-02-01 00:00:00

abstract：INTRODUCTION:Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could ...

journal_title：Pharmacogenomics

authors： Yen-Revollo JL,Auman JT,McLeod HL

更新日期：2008-11-01 00:00:00

abstract：:The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

journal_title：Pharmacogenomics

authors： Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

更新日期：2014-12-01 00:00:00

abstract：AIM:To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. PATIENTS & METHODS:In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on stati...

journal_title：Pharmacogenomics

authors： Leusink M,Maitland-van der Zee AH,Ding B,Drenos F,van Iperen EP,Warren HR,Caulfield MJ,Cupples LA,Cushman M,Hingorani AD,Hoogeveen RC,Hovingh GK,Kumari M,Lange LA,Munroe PB,Nyberg F,Schreiner PJ,Sivapalaratnam S,de Ba

更新日期：2016-04-01 00:00:00

abstract：AIM:To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS & METHODS:DNA samples from 178 patients were subjected to copy...

journal_title：Pharmacogenomics

authors： Scott SA,Patel M,Martis S,Lubitz SA,van der Zee S,Yoo C,Edelmann L,Halperin JL,Desnick RJ

更新日期：2012-02-01 00:00:00

abstract：:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

journal_title：Pharmacogenomics

authors： Schmidt WM

更新日期：2004-06-01 00:00:00

abstract：OBJECTIVES:Three exonic single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene, 516G>T, 785A>G and 1459C>T, have been described to be associated with functional changes in the CYP2B6 catalytic activity or protein expression. They are therefore of potential clinical importance for drug efficacy ...

journal_title：Pharmacogenomics

authors： Rohrbacher M,Kirchhof A,Geisslinger G,Lötsch J

更新日期：2006-10-01 00:00:00

abstract：:Leukotriene overproduction is the major characteristic of aspirin-intolerant asthma (AIA). Most studies examining the molecular genetic mechanisms of AIA have focused on leukotriene-related genes, including ALOX5, LTC4S, TXA2R and prostanoid-receptor genes. One study suggested that the human leukocyte antigen (HLA) al...

journal_title：Pharmacogenomics

authors： Kim SH,Hur GY,Choi JH,Park HS

更新日期：2008-01-01 00:00:00

abstract：:Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

journal_title：Pharmacogenomics

authors： Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

更新日期：2008-12-01 00:00:00

abstract：:The first observations of inherited differences in drug effects in the 1950s led to the recognition of a genetic basis for drug response. With the development of genetics and molecular biology, it became clear that certain drug responses could be associated with specific genetic variations or polymorphisms. There are ...

journal_title：Pharmacogenomics

authors： Ferentz AE

更新日期：2002-07-01 00:00:00

abstract：UNLABELLED:Warfarin, a widely prescribed oral anticoagulant, is used for the prevention of thromboembolism. Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements. However, it is likely that other genes could also affect warfarin dose. AIMS:In this study, we aimed to identi...

journal_title：Pharmacogenomics

authors： Lee MT,Chen CH,Chou CH,Lu LS,Chuang HP,Chen YT,Saleem AN,Wen MS,Chen JJ,Wu JY,Chen YT

更新日期：2009-12-01 00:00:00

abstract：AIM:This study aimed to explore the role of miRNAs in rifampin-mediated induction of CYP3A4 in HepaRG cells. MATERIALS & METHODS:Microarray was performed to determine the expression of miRNAs in rifampin-treated HepaRG cells, followed by bioinformatics and luciferase reporter gene assay to analyze miRNAs that directly...

journal_title：Pharmacogenomics

authors： Yan L,Liu J,Zhao Y,Nie Y,Ma X,Kan Q,Zhang L

更新日期：2017-01-01 00:00:00

abstract：:Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulat...

journal_title：Pharmacogenomics

authors： Muluhngwi P,Valdes R Jr,Fernandez-Botran R,Burton E,Williams B,Linder MW

更新日期：2019-04-01 00:00:00

abstract：:The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

journal_title：Pharmacogenomics

authors： Aubrecht J,Caba E

更新日期：2005-06-01 00:00:00

abstract：:The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

journal_title：Pharmacogenomics

authors： Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

更新日期：2012-11-01 00:00:00

abstract：INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be...

journal_title：Pharmacogenomics

authors： Krajinovic M,Robaey P,Chiasson S,Lemieux-Blanchard E,Rouillard M,Primeau M,Bournissen FG,Moghrabi A

更新日期：2005-04-01 00:00:00

abstract：:Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

journal_title：Pharmacogenomics

authors： Molokhia M,McKeigue P

更新日期：2006-06-01 00:00:00

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：:The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

journal_title：Pharmacogenomics

authors： Barrot CC,Woillard JB,Picard N

更新日期：2019-06-01 00:00:00

abstract：:Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

journal_title：Pharmacogenomics

authors： Zuiverloon TC,Theodorescu D

更新日期：2017-08-01 00:00:00

abstract：AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...

journal_title：Pharmacogenomics

authors： Balboa E,Duran G,Lamas MJ,Gomez-Caamaño A,Celeiro-Muñoz C,Lopez R,Carracedo A,Barros F

更新日期：2010-06-01 00:00:00

abstract：:Biobanking became a necessity for translating genetic discoveries into clinical practice. Approaches to personalized medicine require a new model system for functional and pharmacogenomic studies of a variety of accumulating genetic variations, as well as new research environments such as biobankomics. Human lymphobla...

journal_title：Pharmacogenomics

authors： Nam HY,Shim SM,Han BG,Jeon JP

更新日期：2011-06-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：:The current paradigm of human genetics research is to analyze variation of a single data type (i.e., DNA sequence or RNA levels) to detect genes and pathways that underlie complex traits such as disease state or drug response. While these studies have detected thousands of variations that associate with hundreds of co...

journal_title：Pharmacogenomics

authors： Holzinger ER,Ritchie MD

更新日期：2012-01-01 00:00:00

abstract：:Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

journal_title：Pharmacogenomics

authors： Lee AK,Bishop JR

更新日期：2011-07-01 00:00:00

abstract：INTRODUCTION:Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in cardiovascular risk, but is limited by a potential increase in adverse effects, thereby justifying optimization of LDL-C reduction with minimal risk. The org...

journal_title：Pharmacogenomics

authors： Couvert P,Giral P,Dejager S,Gu J,Huby T,Chapman MJ,Bruckert E,Carrié A

更新日期：2008-09-01 00:00:00

abstract：:Aim: The CYP2D6 gene is highly polymorphic and harbors population specific alleles that define its predominant metabolizer phenotype. This study aimed to identify polymorphisms in Indian population owing to scarcity of CYP2D6 data in this population. Materials & methods: The CYP2D6 gene was resequenced in 105 south In...

journal_title：Pharmacogenomics

authors： Manoharan A,Shewade DG,Ravindranath PA,Rajkumar RP,Ramprasad VL,Adithan S,Damodaran SE

更新日期：2019-07-01 00:00:00

abstract：AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

journal_title：Pharmacogenomics

authors： Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

更新日期：2008-07-01 00:00:00